Chronic Liver Disease (CLD)
Definition
Chronic Liver Disease (CLD) refers to progressive destruction and regeneration of liver parenchyma occurring over >6 months, leading to:
- Fibrosis
- Architectural distortion
- Portal hypertension
- Liver dysfunction
- Eventually cirrhosis and hepatic failure
CLD is a dynamic process ranging from:
- Chronic hepatitis → fibrosis → compensated cirrhosis → decompensated cirrhosis → acute-on-chronic liver failure (ACLF)
|
Condition |
Definition |
Features |
|
Acute Liver Failure (ALF) |
Rapid development of severe acute liver injury with coagulopathy and hepatic encephalopathy in a patient without pre-existing cirrhosis or chronic liver disease -Classical definition from American Association for the Study of Liver Diseases (AASLD) |
– Acute liver injury – INR ≥1.5 – Any degree of hepatic encephalopathy – No prior cirrhosis
|
|
Chronic Liver Disease (CLD) |
Progressive hepatic injury and fibrosis persisting for >6 months, leading to distortion of liver architecture and impaired liver function |
– Chronic inflammation/fibrosis – May or may not have cirrhosis – May be compensated or decompensated |
|
Compensated CLD/Cirrhosis |
Cirrhosis without overt clinical complications of portal hypertension or liver failure Patients may be asymptomatic despite significant fibrosis |
No history of: – Ascites – Variceal bleed – Hepatic encephalopathy – Jaundice related to liver failure |
|
Decompensated CLD/Cirrhosis |
Cirrhosis with development of clinically evident complications due to portal hypertension or hepatic insufficiency Defines transition to advanced disease with markedly reduced survival |
Presence of one or more: – Ascites – Variceal hemorrhage – Hepatic encephalopathy – Jaundice |
|
Acute-on-Chronic Liver Failure (ACLF) |
Acute deterioration in a patient with chronic liver disease/cirrhosis associated with organ failure(s) and high short-term mortality Definitions vary among societies (EASL, APASL, NACSELD) |
– Underlying CLD/cirrhosis – Acute precipitating event – Organ failure(s) – High 28-day mortality |
Etiology of CLD
1. Alcohol-related Liver Disease (ALD)
2. Nonalcoholic Fatty Liver Disease (NAFLD)/MASLD
3. Chronic Hepatitis B
4. Chronic Hepatitis C
5. Autoimmune Hepatitis (AIH)
6. Primary Biliary Cholangitis (PBC)
7. Primary Sclerosing Cholangitis (PSC)
8. Wilson Disease
9. Hemochromatosis
10. Alpha-1 Antitrypsin Deficiency
11. Drug-induced Chronic Liver Disease
12. Methotrexate
13. Amiodarone
14. Isoniazid
15. Valproate
16. Budd-Chiari Syndrome
17. Congestive Hepatopathy
18. Cryptogenic Cirrhosis
Pathophysiology
Central Event: Hepatic Fibrosis
Repeated liver injury causes:
- Hepatocyte injury —Inflammation—Stellate cell activation—Collagen deposition—Fibrosis
Hepatic Stellate Cells
Normally store vitamin A.
When activated:
- Transform into myofibroblasts
- Produce collagen
- Cause fibrosis
Progression to Cirrhosis
Fibrosis progresses to:
- Regenerative nodules—-Distorted architecture—-Increased vascular resistance—-Portal hypertension
Consequences
|
Consequence |
Mechanism |
|
Ascites |
Portal pressure + sodium retention |
|
Varices |
Portosystemic collaterals |
|
Splenomegaly |
Congestion |
|
Hepatorenal syndrome |
Splanchnic vasodilation |
|
Hepatic encephalopathy |
Ammonia accumulation |
Hemodynamic Changes in CLD
Hyperdynamic Circulation
Features:
- Increased cardiac output
- Decreased SVR
- Splanchnic vasodilation
Mediators:
- Nitric oxide
- Cytokines
Clinical Features
Symptoms
|
Early |
Advanced |
|
Fatigue |
Ascites |
|
Malaise |
Jaundice |
|
Anorexia |
GI bleed |
|
Weight loss |
Encephalopathy |
|
RUQ discomfort |
Edema |
Signs of Chronic Liver Disease
General Signs
|
Sign |
Mechanism |
|
Jaundice |
Hyperbilirubinemia |
|
Muscle wasting |
Catabolism |
|
Cachexia |
Malnutrition |
|
Clubbing |
Chronic disease |
Cutaneous Signs
|
Sign |
Cause |
|
Spider angioma(dilated cutaneous arterioles with a central red spot and red extensions that radiate outward like a spider’s web in the territory of SVC) |
Hyperestrogenism |
|
Palmar erythema |
Vasodilation |
|
Leukonychia |
Hypoalbuminemia |
|
Terry’s nails |
Chronic disease |
|
Bruising |
Coagulopathy |
Endocrine Manifestations
|
Feature |
Cause |
|
Gynecomastia |
Estrogen excess(catabolism of estrogen becomes impaired,) |
|
Testicular atrophy |
Hormonal imbalance |
|
Loss of body hair |
Hypogonadism |
Abdominal Findings
|
Finding |
Cause |
|
Hepatomegaly |
Fatty liver/congestion |
|
Splenomegaly |
Portal hypertension |
|
Ascites |
Portal HTN |
|
Caput medusae |
Collaterals |
Neurological Features
- Hepatic encephalopathy
- Asterixis
- Confusion
- Sleep reversal
- Coma
Staging of CLD
Compensated Cirrhosis
No major complications.
Patients may be asymptomatic.
Median survival:12 years
Decompensated Cirrhosis
Presence of:
- Ascites
- Variceal bleed
- Hepatic encephalopathy
- Jaundice
Median survival:~2 years
Child-Turcotte-Pugh (CTP) Score
|
Parameter |
1 |
2 |
3 |
|
Bilirubin |
<2 |
2–3 |
>3 |
|
Albumin |
>3.5 |
2.8–3.5 |
<2.8 |
|
INR |
<1.7 |
1.7–2.3 |
>2.3 |
|
Ascites |
None |
Mild |
Severe |
|
Encephalopathy |
None |
Grade I–II |
Grade III–IV |
Classes
|
Class |
Score |
Survival |
|
A |
5–6 |
Best |
|
B |
7–9 |
Intermediate |
|
C |
10–15 |
Worst |
MELD Score
Used for transplant priority.
Uses:
- Bilirubin
- INR
- Creatinine
- Sodium (MELD-Na)
Higher score = worse prognosis.
Laboratory Findings
LFT Pattern
|
Test |
Finding |
|
Bilirubin |
Increased |
|
AST/ALT |
Elevated |
|
Albumin |
Decreased |
|
INR/PT |
Prolonged |
|
Platelets |
Low |
AST and ALT are usually elevated two to three times of normal limit, but normal levels of these markers do not rule out cirrhosis. As in compensated CLD LFTs may be normal in cirrhosis.
Characteristic Clues
|
Pattern |
Suggestion |
|
AST>ALT (2:1) |
Alcoholic liver disease |
|
Very high ferritin |
Hemochromatosis |
|
Low ceruloplasmin |
Wilson disease |
|
AMA positive |
PBC |
CBC
|
Finding |
Suggests |
|
Thrombocytopenia |
Portal hypertension |
|
Macrocytosis |
Alcohol use |
|
Anemia |
GI bleed/nutrition |
Renal Function
Important because cirrhosis affects kidneys:
- Creatinine
- Sodium
- Urea
Imaging in CLD
Ultrasound
|
Ultrasound Finding |
Significance |
|
Coarse echotexture |
Fibrosis |
|
Nodular liver |
Cirrhosis |
|
Splenomegaly |
Portal hypertension |
|
Dilated portal vein |
Portal hypertension |
|
Ascites |
Decompensation |
|
Collaterals |
Advanced disease |
Doppler
Assesses:
- Portal vein flow
- Hepatic vein thrombosis
- Portal hypertension
CT/MRI
Useful for:
- HCC detection
- Vascular anatomy
- Complications
Elastography
Measures liver stiffness.
Examples:FibroScan
Helps assess fibrosis noninvasively.
Liver Biopsy
Gold standard for fibrosis assessment.
Indications:
- Uncertain diagnosis
- Autoimmune disease
- Staging
Contraindications:
- Severe coagulopathy
- Massive ascites
After diagnosing CLD, determine cause:
Viral-HBsAg,Anti-HCV
Alcohol-related
- Alcohol history,AST:ALT >2
Metabolic
- Ferritin/transferrin saturation
- Ceruloplasmin
- Alpha-1 antitrypsin
Autoimmune
- ANA—ASMA—AMA—IgG levels
MASLD/NAFLD
- Metabolic syndrome features
- Imaging showing steatosis
Major Complications of CLD
1. Ascites
Most common complication.
Mechanism:
Portal HTN + RAAS activation + sodium retention
2. Spontaneous Bacterial Peritonitis (SBP)
Defined as:
Ascitic PMN ≥250/mm³ without surgically treatable source.
Common organisms:
- E. coli—Klebsiella—Streptococci
3. Variceal Hemorrhage
Due to portal hypertension.
Sites
- Esophageal varices—Gastric varices
4. Hepatic Encephalopathy
Brain dysfunction due to liver failure/portosystemic shunting.
5. Hepatorenal Syndrome (HRS)
6. Hepatopulmonary Syndrome (HPS)
Triad:Liver disease—Hypoxemia—Intrapulmonary vasodilation
7. Portopulmonary Hypertension
Pulmonary arterial hypertension associated with portal HTN.
8. Coagulopathy
Liver synthesizes clotting factors.
Findings:Elevated INR—Thrombocytopenia
However:Patients may be both bleeding and thrombotic.
9. Hepatocellular Carcinoma (HCC)
Major complication of cirrhosis.
Surveillance
Every 6 months:
- Ultrasound
- ± AFP
ACLF (Acute-on-Chronic Liver Failure)
Acute decompensation in CLD with organ failure and high mortality.
Common precipitants:
- Infection
- Alcohol binge
- GI bleed
- HBV reactivation
Patients with chronic liver disease require regular surveillance to detect complications early and monitor disease progression. Routine evaluation should include CBC, CMP, and prothrombin time/INR approximately every 3–4 months.
Screening upper gastrointestinal endoscopy should be performed to detect asymptomatic esophageal varices. If no varices are identified on the initial endoscopy, repeat endoscopic screening is generally recommended after 2 years.
Management of CLD
General Measures
|
Measure |
Importance |
|
Alcohol abstinence |
Essential |
|
Vaccination |
HAV/HBV |
|
Nutrition |
High protein unless contraindicated |
|
Avoid hepatotoxic drugs |
Prevent worsening |
|
Surveillance |
HCC/varices |
Nutritional Therapy
Malnutrition is Common
Recommendations:
- 30–35 kcal/kg/day
- Protein: 1.2–1.5 g/kg/day
- Late evening snack
Avoid prolonged fasting.
Causes of Death in CLD
|
Cause |
Mechanism |
|
Sepsis |
Immune dysfunction |
|
GI bleed |
Varices |
|
Renal failure |
HRS |
|
ACLF |
Multiorgan failure |
|
HCC |
Malignancy |
REFERENCES
1.Sharma A, Nagalli S. Chronic Liver Disease. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554597/